To test, whether the LMP-1 peptide variants have an additional effect on the proliferation of EBV+ lymphoma cells, we first co-cultured the EBV-infected K562-CR2-HLA-E*0103/0103 or EBV-infected HLA-E*0101/0101 cells or NKG2A+NKG2C- NK cells alone with an LMP-1 peptide pool, containing all LMP-1 peptide variants. This evidence concerns the gene KLRC2 and lymphoma.